Form 4: AnaptysBio Director Sells Shares to Cover Tax Obligations from RSU Vesting

AnaptysBio, Inc. Director Dennis M. Fenton sold 3,015 shares of common stock for $23.97 per share on June 18, 2025, as part of a pre-arranged 10b5-1 trading plan to satisfy tax liabilities from restricted stock unit vesting.

Summary

• Dennis M. Fenton, a Director of AnaptysBio, Inc. (ANAB), reported the sale of 3,015 shares of common stock.
• The transaction occurred on June 18, 2025, with shares sold at a price of $23.97 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Fenton on March 22, 2024.
• The primary reason for the sale was to satisfy a portion of the tax obligation incurred due to the vesting of restricted stock units (RSUs) on June 15, 2025.
• Following this transaction, Mr. Fenton's direct beneficial ownership of AnaptysBio common stock stands at 4,965 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a sale by a director, it was pre-planned under a 10b5-1 plan and explicitly for tax purposes related to RSU vesting, which is a common and non-discretionary reason for insider selling, typically not viewed negatively by the market.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and non-discretionary transaction, which often mitigates concerns about insider selling.
• The sale was specifically for tax obligations related to RSU vesting, a common and expected event for executives and directors receiving equity compensation.

Negatives

• A director selling shares, even for tax purposes, reduces their direct ownership stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context or trends. It reflects a common practice for executives to sell shares to cover tax liabilities arising from equity compensation.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in a director's direct ownership, but given it's for tax purposes and pre-planned, it is unlikely to significantly impact shareholder sentiment or the stock price.
• Employees: No direct impact mentioned.

Key Dates

Keywords

AnaptysBio, ANAB, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan, Restricted Stock Units, Tax Obligation, Equity Compensation